Clinical Policy: Electric Tumor Treating Fields (Optune)
Customize your policy alerts
Sign up for communitycareindependentpracticeassociation Policy CP.MP.145 alerts
Get alerted when Policy CP.MP.145 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity and prior-authorization coverage for Optune electric tumor treating fields in adults with newly diagnosed or recurrent glioblastoma. It also addresses continuation therapy, contraindications, unsupported indications, NovoTal planning software, and related billing codes.
The October 2026 revision requires chemoradiation, rather than radiation alone, to be completed before Optune is used with temozolomide for newly diagnosed glioblastoma.
The October 2026 revision added a requirement that newly diagnosed glioblastoma show no evidence of progression by RANO criteria.
The policy added an age restriction requiring adults older than 22 years for medically necessary TTF therapy.
The policy added an 18-hours-per-day device-wear requirement for initial therapy and continuation therapy, including prior-period compliance for continuation.
The performance-status threshold was revised from a Karnofsky Performance Status of at least 70 to at least 60.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.